Drug intelligence / Profile preview

UHE-101

Development stage: Phase 2
Lead developer: Therapeutics, Inc.
Modality: Small Molecules
Administration: Topical

Overview

UHE-101 is a small molecule drug developed by Therapeutics, Inc. for dermatological use, specifically as a topical cream formulation. Its primary indication is the treatment of acne vulgaris. The drug has been evaluated in at least one Phase 2 clinical trial as a 1% cream applied topically twice daily for 12 weeks in subjects with facial acne vulgaris. The mechanism of action and molecular target have not been publicly disclosed. As of the latest update, its highest global R&D status is "Pending," and it has not received regulatory approval[1].

Beyond the preview

Go deeper on UHE-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UHE-101.

Explore the full profile